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Abstract
Background and Aims:
 Mesenteric lymph nodes are sites in which translocated bacteria incite and 
progress immunological responses. For this reason, understanding the microbiome of mesenteric 
lymph nodes in inflammatory bowel disease is important. The bacterial profile of Crohn’s disease 
mesenteric lymph nodes has been analysed using culture-independent methods in only one 
previous study. This study aimed to investigate the mesenteric lymph node microbiota from both 
Crohn’s disease and ulcerative colitis patients.
Methods: Mesenteric lymph nodes were collected from Crohn’s disease and ulcerative colitis 
patients undergoing resection. Total DNA was extracted from mesenteric lymph nodes and 
assessed for the presence of bacterial DNA [16S]. All work was completed in a sterile environment 
using aseptic techniques. Samples positive for 16S DNA underwent next-generation sequencing, 
and the identity of bacterial phyla and species were determined.
Results: Crohn’s disease mesenteric lymph nodes had a distinctly different microbial profile to 
that observed in ulcerative colitis. The relative abundance of Firmicutes was greater in nodes from 
ulcerative colitis patients, whereas Proteobacteria were more abundant in Crohn’s disease. Although 
species diversity was reduced in the mesenteric lymph nodes of patients with Crohn’s disease, 
these lymph nodes contained greater numbers of less dominant phyla, mainly Fusobacteria.
Conclusion: This study confirms that there are distinct differences between the Crohn’s disease 
and ulcerative colitis mesenteric lymph node microbiomes. Such microbial differences could aid in 
the diagnosis of Crohn’s disease or ulcerative colitis, particularly in cases of indeterminate colitis at 
time of resection, or help explain their mechanisms of development and progression.
Key Words:  Inflammatory bowel disease; microbiome; mesenteric lymph nodes
Abbreviations:  MLNs, mesenteric lymph nodes; IBD, inflammatory bowel disease; CD, Crohn’s disease, UC, ulcerative col-
itis; DNA, deoxyribonucleic acid; PCR, polymerase chain reaction; UHL, University Hospital Limerick; RNA, ribonucleic 
acid; PBS, phosphate-buffered saline; IDT, Integrated DNA Technologies; OTU, operational taxonomic unit; GOLD, Genome 
OnLine Database; RDP, Ribosomal Database Project; CI, confidence interval; PCoA, Principal Coordinates Analysis.
1. Introduction
Inflammatory bowel diseases [IBDs], which include Crohn’s disease 
[CD] and ulcerative colitis [UC], are thought to result from an overly 
aggressive immune response in genetically susceptible individuals 
to an environmental factor, such as gut commensals.1,2 The highest 
prevalence rates worldwide of CD and UC are found in Europe, with 
322 and 505 cases per 100 000 persons, respectively.3
The human gut microbiota has been investigated to a great 
extent, in both health and disease, particularly for gastrointestinal 
diseases, such as IBD. The earliest of these studies investigated bac-
terial content in faecal matter using conventional culture meth-
ods.4–11 Following this, the microbial profile of mucosal tissue was 
explored because it was believed to be a more accurate representa-
tion of the gut microbiota. Indeed, it has since been proven, by recent 
comprehensive studies, that significant differences exist between the 
bacterial groups found in the mucosa and those in faecal matter.12,13 
Culture methods were used once again, to ascertain the mucosal 
tissue microbial profile.14–17 These studies provided a preliminary 
insight into the human gut microbiota; however, it has been esti-
mated that up to 70–80% of intestinal bacteria are unculturable.18,19 
For this reason, the development of culture-independent methods 
has significantly advanced our knowledge of gastrointestinal flora.20–
22 These techniques have been used to great effect in establishing a 
gut microbiota profile for health and for IBD.
In healthy individuals, the phyla Firmicutes [a phylum includ-
ing Enteroccocaceae, Clostridiaceae, and Ruminococcaceae] 
and Bacteroidetes [a phylum including Bacteroidaceae, 
Porphyromonadaceae, Prevotellaceae, Rikenellaceae, and 
Flavobacteriaceae] dominate, with lower abundance of other phyla, 
mainly Proteobacteria [a phylum including Enterobacteriaceae, 
and Burkholderiaceae] and Actinobacteria [a phylum including 
Mycobacteriaceae, Micrococcaceae, and Streptomycineae].23–25 The 
IBD gut microbiota displays dysbiosis when compared with that of 
healthy individuals, and there is a marked reduction in bacterial diver-
sity, related particularly to the Firmicutes and Bacteroidetes phyla.26,27 
This coincides with an increase in Gammaproteobacteria [which 
includes Enterobacteriaceae and Pseudomonadaceae].26 The CD micro-
biome displays greater dysbiosis than that found in UC - specifically, 
a greater  reduction in microbial diversity, with a more altered and 
less stable microbiome composition.28 Inflamed mucosal tissue from 
CD patients contains higher levels of Bacteroidetes and Fusobacteria 
[includes Fusobacterium nucleatum], whereas Proteobacteria and 
Firmicutes [in particular Clostridiaceae, Enterobacteriaceae, and 
Ruminococcaceae] are more frequently observed in inflamed UC 
mucosa.29,30 Despite these changes, the microbiome of UC patients has 
been described as one that is more similar to healthy individuals.31,32
Although mesenteric lymph nodes [MLNs] have been associated 
with initiation of immunological responses to bacterial transloca-
tion,33–35 the importance of the MLN microbiome in IBD remains 
unclear.
To our knowledge, only one study has assessed the microbial 
content of MLNs in CD using culture-independent methods, report-
ing a bacterial profile similar to that of the CD gut microbiome, 
and no study has described the microbiome of UC patient MLNs.36 
This is despite various culture-dependent studies demonstrating 
bacterial translocation to MLNs and mesenteric fat in IBD.37–39 
Consistently, the most common organism detected in the MLNs 
in IBD was Escherichia coli37,38,40; however, the full diversity of the 
MLN microbiota has not yet been elucidated. Addressing this gap in 
knowledge may prove valuable in better understanding these distinct 
diseases. Our group has recently highlighted the potential role of 
the mesentery in IBD and has demonstrated that surgical recurrence 
rates for ileocolic CD patients are significantly reduced when the 
mesentery, and MLNs, are removed during resection.41,42 As the simi-
larity of the MLN and mucosal microbiome in CD has been compre-
hensively reported previously, and selective bacterial translocation 
from the gut to the nodes effectively refuted,36 our interest concerned 
the variation in bacteria in MLNs from IBD patients. Therefore, we 
aimed to investigate and compare the microbial profile of MLNs 
from CD and UC patients diagnosed pathologically, using culture-
independent methods for the first time.
2. Methods
2.1. Ethical approval
Ethical approval was obtained from the Research Ethics Committee 
of University Hospital Limerick [UHL].
2.2. Inclusion and exclusion criteria
All adult patients [≥18 years] undergoing resection for histopatho-
logically diagnosed CD or UC in UHL from October 2015 to 
September 2016 were recruited. Patients were excluded if they had 
been diagnosed with colorectal cancer previously or were suspected 
of having colorectal cancer at the time of operation, so as not to 
interfere with pathologic analysis.
2.3. Mesenteric lymph node harvest
Where possible, IBD patients in UHL undergo resections that include 
the mesentery,41 allowing for greater MLN yields. Diseased intestine, 
along with associated mesentery, was resected and placed immedi-
ately in a sterile surgical tray. The resected specimen was kept in the 
sterile surgical area until the lymph nodes could be harvested. Lymph 
nodes were harvested from resected specimens in a sterile environ-
ment, which was outside the sterile surgical area but under the same 
atmospheric pressure, using aseptic techniques and sterile surgical 
instruments. The lymph nodes were identified and cut from the mes-
entery by a trained colorectal surgeon. Nodes were placed, without 
handling, into sterile microtubes. Although desirable, it was not pos-
sible to utilize nodes as morphological controls [e.g. nodes halved and 
sent for both 16S testing and pathological analysis]. Allprotect Tissue 
Reagent [Qiagen, UK] was added to each specimen tube until the tis-
sue was fully immersed. A separate control sample of Allprotect Tissue 
Reagent was also obtained. Samples were kept at room temperature 
for a maximum of 2 h before transfer to long-term storage at –80°C.
2.4. DNA extraction
Lymph nodes were thawed on ice for 30 min before processing. All 
work was performed in sterile conditions in a Class II biosafety cab-
inet, using aseptic techniques and DNase-free instruments and con-
sumables. Excess Allprotect Tissue Reagent was removed, and nodes 
were washed in 1  mL sterile phosphate-buffered saline (PBS; pH 
7.4 [137 mM NaCl; 2.68 mM KCl; 9.94 mM Na2HPO4; 1.76 mM 
KH2PO4]). MLNs were weighed, and samples of ~25 mg were used 
for DNA extraction. Total DNA was extracted from samples using 
a QIAamp cador pathogen Mini Kit [Qiagen, UK], using the manu-
facturer’s instructions. In brief, tissue lysis buffer [180  µL; Buffer 
ATL] was added to the node tissue and the sample was homogenized 
for 1  min using a motorized pestle. Proteinase K enzyme [20 µL] 
was added to this to commence enzymatic tissue digestion. Samples 
were incubated overnight at 56°C with constant shaking. Following 
this, digested tissue [200 µL] mixed with sterile PBS [200 µL] was 
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transferred to Pathogen Lysis Tubes S [Qiagen, UK], pre-prepared 
with tissue lysis buffer [Buffer ATL] and anti-foaming reagent 
[Reagent DX] [100 µL total] for mechanical disruption of hard-to-
lyse bacteria by glass beads. This was completed by vigorous shaking 
for 10 min. Buffer VXL [100 µL], which ensures the inactivation of 
nucleases when in the presence of proteinase [100 µL], was added 
to the pre-treated samples [enzymatically digested and mechanically 
disrupted], mixed well, and left to incubate at room temperature for 
15 min. Binding reagent [Buffer ACB; 350 µL] was added to sam-
ples, mixed well, and transferred to spin columns. DNA was then 
isolated following a series of centrifugations using QIAamp spin col-
umns and buffer solutions. DNA was eluted in 100 µL elution buffer 
[Buffer AVE] [2 × 10-min elutions], and quantity and quality were 
assessed using the 260/280 function on the Spectrostar Nano plate 
reader LVis plate function [BMG Labtech]. Extracted DNA was 
stored at –20°C for subsequent polymerase chain reaction [PCR].
2.5. Polymerase chain reaction amplification of 
16S DNA
The presence or absence of bacteria in MLNs was confirmed by PCR 
amplification of 16S [bacterial] DNA. All work was carried out on a 
dedicated clean PCR bench, in sterile conditions and using sterile and 
DNase-free instruments and consumables. Suitable positive [extracted 
DNA from a combined mixture of bacterial species] and negative [no 
template DNA and extracted DNA from PBS false extraction] con-
trols were included. The PCR reaction included HotStarTaq Master 
Mix [25 µL], 500 ng template DNA, 0.5 µM 16S rRNA Forward 
primer, and 0.5 µM 16S rRNA Reverse primer. The total volume of 
the PCR reaction was 50 µL; the remaining volume was made up 
with PCR grade water [HotStarTaq Master Mix Kit, Invitrogen]. The 
forward and reverse primers were ready-made primers obtained from 
Integrated DNA Technologies [IDT] and are designed to incorporate 
a large portion of the 16S gene: For [5-AGA GTT TGA TCC TGG 
CTC AG-3] and Rev [5-ACG GCT ACC TTG TTA CGA CTT-3]. 
Reactions were performed using a Kyratec Thermal Cycler [Kyratec, 
Australia]: heat activation step at 95°C for 15  min; 30 cycles of 
denaturation at 94°C for 30  s, annealing at 57.49°C for 30  s and 
extension at 72°C for 60 s; and the final extension step at 72°C for 
10  min. Amplicons were extracted using GenElute PCR Clean-Up 
Kit [Sigma Aldrich] as per the manufacturer’s instructions. Amplified 
DNA was eluted in 50 µL elution buffer [from kit], and presence, 
quantity, and quality were assessed using the 260/280 function on 
the Spectrostar Nano plate reader. DNA quality was also assessed 
by visualization on a 1% agarose gel. Lymph nodes were deemed 
as “16S negative” when: [i] no quantity of DNA was detected on 
the Spectrostar Nano plate reader, [ii] the 260/280 ratio and graph 
profiles were not similar to that expected of DNA content, and [iii] 
a large quantity of the amplified product was ran on a 1% agarose 
gel, and no DNA band was visualized. Amplified DNA was stored at 
–20°C for future species identification through sequencing.
2.6. Next-generation sequencing
Library preparation and sequencing were completed in the Teagasc 
Sequencing Centre [Cork, Ireland] as follows: DNA was quantified 
using the Qubit High Sensitivity Kit [Life Technologies], standard-
ized, and then used as a template for PCR. PCR primers and condi-
tions are essentially as outlined in the Illumina 16S Metagenomic 
Sequencing Library preparation guide [Illumina] with the following 
exceptions: For the initial 16S PCR, the process was performed using 
Kapa Robust [Roche] in 50 µl reaction volumes, and 30 cycles were 
used in the PCR. The V3–V4 variable regions were amplified by the 
primers. These regions are the suggested target for the Illumina 16S 
Metagenomic Sequencing system as previously found to be the opti-
mum primer pair for sequencing-based species diversity studies.43,44 
Products were then cleaned with an appropriate volume of Ampure 
beads and eluted in 30 µl per sample. This was then used as the 
template for the index PCRs as outlined in the protocol [Illumina]. 
Library quantification, normalization, and pooling were as outlined 
in the protocol. After pooling, the sample was re-quantified by qPCR 
using the Kapa Library Quantification Kit for Illumina [Roche] and 
run on an Agilent high-sensitivity chip [Agilent]. Library denatur-
ation and MiSeq sample loading were then performed according to 
the manufacturer’s instructions [Illumina]. PhiX was spiked into the 
final pool at 20% [v/v], and sequencing was performed using a 500-
cycle V2 chemistry kit [Illumina]. Previous studies using the Illumina 
MiSeq system and primer pairs targeting the V3–V4 variable regions 
have identified bacteria to species level.45,46 The V3–V4 variable 
regions are commonly used to investigate the gut microbiome and to 
detect intestinal bacterial species.45–48
2.7. Bioinformatics
Illumina reads were filtered on the basis of quality [removal of 
low-quality nucleotides at the 3′ end, in addition to bases where 
quality was below 20 in a trimming window] and length [removal 
of sequences with <200 bp] with PRINSEQ,49 and the paired-end 
reads with a minimum overlap of 20 bp were joined using Fastq-
join.50 A pipeline [a series of data-processing events] was generated, 
using clean reads only [i.e. filtered reads described above], to cluster 
sequences [from next-generation sequencing data] with 97% iden-
tity to obtain Operative Taxonomic Units [OTUs] using a closed-
reference USEARCH v7.0 algorithm [Edgar RC. 2010] and remove 
chimeric OTUs against the Genome OnLine Database [GOLD]. An 
OTU represents a group of similar 16S rRNA sequences that theoret-
ically reflect shared species identity. However, while a 97% threshold 
is sufficient for diversity studies, similarity thresholds of >98% are 
required to identify species definitively. The taxonomic assignment 
of these OTUs was obtained against the Ribosomal Database Project 
[RDP; http://rdp.cme.msu.edu/].51 Beta-diversity was determined 
using QIIME,52 and additional analysis were performed with the R 
package, phyloseq.53
2.8. Statistical analysis
Data are presented as mean ± 95% confidence interval [CI]. To 
determine phyla, family, and species OTUs, data were statistically 
analysed by PERMANOVA for beta-diversity. All other statistical 
analyses were completed in SPSS v22 [SPSS Inc., Chicago, USA]. An 
independent two-tailed t-test was used to compare parametric vari-
ables, and a Mann–Whitney U test was utilized for non-parametric 
comparisons. A Kruskal-Wallis test was used to determine the most 
abundant bacterial genus in MLNs from patients with CD or UC. 
Species richness estimates were generated using the Chao 1 estimator 
and the Abundance-based Coverage Estimator [ACE], and commu-
nity and species diversity were estimated using the Shannon Diversity 
index. A 5% level of significance was used for all statistical tests.
3. Results
3.1. Patient and MLN characteristics
Thirteen pathologically diagnosed IBD patients [CD: n = 5, 38%; 
UC: n  =  8, 62%] were recruited [Supplementary Table  1]. These 
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underwent 15 surgical procedures for IBD. All patients had intra-
venous antibiotics administered with induction of anaesthesia, 
~15  min before the start of the surgical procedure, as per stand-
ard of care. MLNs were taken from locations along the small bowel 
mesentery and mesocolon [Figure 1A–C]. No biases were observed 
regarding the number of lymph nodes or lymph node diameter irre-
spective of sampling location. There was no evidence of abscesses 
in the MLNs collected. Furthermore, histopathologic analysis of 
resection specimens did not identify the presence of mesenteric 
abscesses. In total, 25% and 24% of MLNs collected from CD and 
UC patients, respectively, did not contain bacterial DNA [Figure 1D, 
E]. Demographics of patients with bacterial DNA–positive nodes are 
provided in Table 1.
3.2. The microbiome of MLNs from CD patients was 
distinctly different to that of MLNs from UC patients
Bacteria from 14 different phyla were detected, irrespective of dis-
ease cohort [Figure 2]. The majority of OTUs belonged to Firmicutes 
and Bacteroidetes, followed by Proteobacteria and Actinobacteria. 
Other phyla, generally less studied and only defined in the last two 
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Figure 1. Mesenteric lymph node [MLN] mapping. [A] Digital image of the small and large bowel with associated continuous mesentery. Source locations of 
MLNs are mapped on the mesentery. [B] Proportions of MLNs taken from each location of ulcerative colitis [UC] mesentery. The majority of lymph nodes were 
taken from the mesorectum [42.9%]. [C] Proportions of MLNs taken from each location of Crohn’s disease [CD] mesentery. The majority of lymph nodes were 
taken from the ileocolic region [87.5%]. [D] Proportions of 16S PCR–positive MLNs taken from each location of UC mesentery. [E] Proportions of 16S PCR–positive 
MLNs taken from each location of CD mesentery.
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decades [e.g. Parcubacteria, Verrucomicrobia], were also detected. 
MLNs were obtained from various locations within the mesentery 
from Patients 5, 6, and 7, such as the mesorectum [M8] and mes-
osigmoid [M9 and M10] from Patient 5, the mesorectum [M11 and 
M12] and right mesocolon [M13] from Patient 6, and the mesen-
tery associated with the caecum [M16], transverse mesocolon [M17 
and M18], mesosigmoid [M15 and M19], and mesorectum [M14] 
from Patient 7 [Figure  2]. The microbial profiles of MLNs taken 
from the same patient were similar, irrespective of sampling loca-
tion. Furthermore, the microbiomes of MLNs taken from areas of 
mesentery that were determined to be disease-free [i.e. those with 
no features of macroscopic inflammation] at time of harvest were 
similar to those nodes taken from areas of diseased mesentery [i.e. 
those which displayed features of inflammation and disease] [Patient 
5, UC, disease-free nodes: M8 and diseased nodes: M9 and M10; 
Patient 13, CD, disease-free nodes: M32 and diseased nodes: M33; 
Figure 2]. There was no readily apparent association between disease 
behaviour and bacterial profiles.
The relative abundance of Firmicutes was greater in UC MLNs 
than in those of CD patients [52.8% ± 6.73% vs 18.6% ± 4.65%; 
p < 0.0001, independent t-test] [Figure 3]. In contrast, MLNs from 
CD patients contained greater abundance of Proteobacteria [36.1% 
± 11.06% vs 11.8% ± 3.63%; p = 0.005, Mann–Whitney U test] and 
greater numbers of less dominant phyla, mainly Fusobacteria [7.3% 
± 4.98% vs 0.3% ± 0.15%; p  <  0.0001, Mann–Whitney U test] 
[Figure  3A, B]. Similar levels of Bacteroidetes and Actinobacteria 
were detected in the two cohorts [Figure  3A, B]. The ratio of 
Firmicutes to Bacteroidetes was increased in UC MLNs [1.613], but 
decreased in CD MLNs [0.705] [Figure 3C].
Interestingly, although Firmicutes was the most abundant 
phylum in UC MLNs, the most abundant bacterial genus was 
Bacteroides [phylum Bacteroidetes], followed by Faecalibacterium 
[phylum Firmicutes] [p  <  0.0001, Kruskal–Wallis test]. In CD 
MLNs, the most abundant bacterial genus was Flavobacterium, 
followed by Bacteroides, both members of phylum Bacteroidetes 
[p  <  0.0001, Kruskal–Wallis test]. Although Faecalibacterium [i.e. 
Faecalibacterium prausnitzii], an important component of the 
healthy gut microbiome, was abundant in UC, it was present to a 
lesser extent in CD [10.9% ± 4.26% vs 1.2% ± 1.15%; p < 0.0001, 
Mann–Whitney U test]. Definitively, a Principal Coordinates 
Analysis [PCoA] of unweighted Unifrac distance demonstrated that 
the bacterial compositions of UC and CD MLNs were distinctly dif-
ferent [Figure 4].
3.3. Diversity and species richness was reduced in 
Crohn’s disease MLNs
Species diversity was estimated using the Shannon Diversity 
index. MLNs from UC patients displayed significantly greater 
microbial diversity than those of CD patients [1.95 ± 0.0035 vs 
0.79 ± 0.0018; p < 0.0001, Mann–Whitney U test] [Figure 5]. We 
determined species richness using the Chao 1 and ACE estimators 
[Supplementary Table  2]. The Chao 1 estimator provides inves-
tigators with a lower bound estimate for species richness.54 This 
indicated greater species richness in CD MLNs than in those of 
UC [237 vs 183] [Supplementary Table 2]. ACE is a more compre-
hensive estimate of species richness, derived from the number of 
rare and common species present in a sample, while also consid-
ering how many more undiscovered species there may be.54 This 
showed greater species richness in UC than in CD MLNs [175–178 
vs 148–156] [Supplementary Table 2], similar to actual raw species 
counts observed.
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4. Discussion
This is the first study to investigate and report distinct differences 
between the microbial profiles of MLNs from UC and CD patients. 
Aided somewhat by the advantageous availability of resected mater-
ial from UC patients, this report also represents the first time that 
the microbiome of MLNs from UC patients has been elucidated. 
In comparison with the reported normal microbiome,23,24 the UC 
MLN microbial profile appears imbalanced in favour of elevated 
Firmicutes relative to Bacteroidetes. Crohn’s disease MLN dysbiosis 
is reflected by overabundance of Proteobacteria [e.g. pathogens such 
as Escherichia, Shigella, Helicobacter, and Salmonella], a decreased 
Firmicutes:Bacteroidetes ratio, and a reduction in species diversity 
and richness. The MLN bacterial profiles remained unchanged irre-
spective of extent of disease or sampling location. Notably, MLNs 
from UC patients who underwent completion proctectomy at least 
6 months following their total colectomy were free of bacterial DNA 
[Patients 10, 12, and 14, Supplementary Table 1]. During this time, 
patients had an end ileostomy in situ. This suggests that, in these 
patients, diversion of the faecal stream allowed clearance of bacterial 
DNA from MLNs by the host immune system.
It has been reported previously that the UC and CD faecal and 
mucosal microbiota are distinct from one another.28–30 Our results 
now confirm that this variation extends to the MLN microbiome. 
This variation differentiates clearly between the diseases, represent-
ing new diagnostic potential, and may also offer targets for innova-
tive therapeutic developments. Approximately 10–15% of IBD cases 
are recorded as indeterminate colitis, meaning a definitive diagnosis 
of CD or UC cannot be made from the resection specimen, or from 
biopsies at colonoscopy.55,56 We believe that the distinctive UC and 
CD MLN microbiota could enable definitive diagnoses at resection, 
potentially revolutionizing prophylactic treatment decisions, patient 
aftercare and survival.
In healthy individuals, the gut microbiota is comprised mainly 
of Firmicutes and Bacteroidetes [~50% and ~40%, respectively]23,24; 
thus the ratio of Firmicutes to Bacteroidetes is often used as an 
indicator of gut microbiota balance. In this study, the relative 
abundance of Firmicutes was greater than Bacteroidetes in MLNs 
from UC patients. Inversely, Bacteroidetes had a greater relative 
abundance than Firmicutes in CD MLNs. The ratio of Firmicutes 
to Bacteroidetes in the MLN microbiome from both CD and UC 
patients has not been characterized previously. However, it has been 
studied to some extent in IBD patient–derived faeces.57,58 Most of 
those studies reported an overall decrease in the ratio relative to 
that of healthy controls.57,58 Conversely, there have also been reports 
of increases in the ratio.59 This disparity could be explained by geo-
graphical, dietary, or treatment factors. In addition, such studies 
have often reported their results based on UC and CD patients 
combined, which could confound the results because there was 
presumption that both diseases share similar microbiomes. One 
previous study has described a decrease in Firmicutes relative to 
Bacteroidetes in UC and CD mucosal tissue when studied separ-
ately.60 This differs from the profile that we have observed in UC 
MLNs. This further differentiates UC and CD and emphasizes the 
need, when analyzing the microbiome of MLNs, to segregate IBD-
derived samples.
Mechanistically, the gut microbiota reportedly restricts transloca-
tion of pathogenic bacteria to the MLN.61 This may be compromised 
in CD but not UC, because the MLN microbiota of CD patients 
display an overabundance of Proteobacteria [known to contain 
numerous pathogenic species]. Likewise, the clearance of harmful 
bacteria from MLNs could also be reduced.61 The MLNs are sites in 
which immunological responses can commence and proliferate.33–35 
It may be that CD MLNs are host to bacterial types that trigger 
more aggressive responses than those of UC MLNs, such as mem-
bers of the Proteobacteria phylum. Conversely, Faecalibacterium, 
which mediates anti-inflammatory effects,62 is present in CD MLNs 
in low proportions compared with the proportions in UC MLNs. Is 
it possible that the pathologic features of CD, which differ greatly to 
that of UC with regard to the increased level of mesenteric involve-
ment, are a consequence of the CD MLN microbiota? It is reason-
able to argue that future work could usefully investigate the role of 
various members of Proteobacteria or Faecalibacterium, or indeed 
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Figure 2. Relative abundance of predominant bacterial phyla in mesenteric lymph nodes [MLNs] from inflammatory bowel disease [IBD] patients. There was a 
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the ratios of one to the other, in the MLNs and in immunological 
responses in both CD and UC. In conclusion, the distinctive UC 
and CD MLN microbiota provide us with a novel diagnostic tool 
for defining indeterminate colitis, an opportunity to understand the 
mechanisms mediating each disease, and the prospect of improving 
patient outcomes.
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